Abdominal Imaging

, Volume 32, Issue 2, pp 253–261 | Cite as

Prostate cancer detection: magnetic resonance (MR) spectroscopic imaging

  • Joan C. VilanovaEmail author
  • Joaquim Barceló


Magnetic resonance spectroscopic imaging (MRSI) represents a noninvasive technique to extend the diagnostic evaluation of prostatic cancer, beyond the morphologic information provided by MR imaging throughout the detection of cellular metabolites (choline and citrate). MRSI combined with the anatomical information provided by MRI can improve the assessment cancer location and extent within the prostate, extracapsular spread and cancer aggressiveness; both before and after treatment. We review the performance of MRI with MRSI and the role in the detection, localization, staging and management of the patient pre- and posttherapy for prostate cancer.


Magnetic resonance (MR) Spectroscopy Prostate neoplasms Tissue characterization Diagnostic radiology Prostate biopsy Staging 


  1. 1.
    Gilliland FD, Hunt WC, Key CR (1996) Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigen era. Urology 48:67–71PubMedCrossRefGoogle Scholar
  2. 2.
    Cooperberg MR, Lubeck DP, Grossfeld GD, et al. (2002) Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavour. J Urol 168:491–495PubMedCrossRefGoogle Scholar
  3. 3.
    Kurhanewicz J, Swanson MG, Nelson SJ, et al. (2002) Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 16:451–463PubMedCrossRefGoogle Scholar
  4. 4.
    Rajesh A, Coakley FV (2004) MR imaging and MR spectroscopic imaging of prostate cancer. Magn Reson Imaging Clin North Am 12:557–579CrossRefGoogle Scholar
  5. 5.
    Tsuda K, Yu KK, Coakley FV, et al. (1999) Endorectal MR imaging of prostate cancer: role of fat suppresion in the detection of extracapsular detection. J Comput Assist Tomogr 23:74–78PubMedCrossRefGoogle Scholar
  6. 6.
    Rouvière O, Raudrant A, Ecochard R et al. (2003) Characterization of timeenhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol 13:931–941PubMedGoogle Scholar
  7. 7.
    Prezioso P, Orlacchio A, Giambattista GD, et al. (2003) Enhancement patterns of prostate cancer in dynamic MRI. Eur Radiol 13:925–930Google Scholar
  8. 8.
    Van Dorsten FA, Van der Graaf M, Engelbrecht MRW, et al. (2004) Combined quantitative dynamic contrast-enhanced MR imaging and 1H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 20:279–287PubMedCrossRefGoogle Scholar
  9. 9.
    Engelbrecht M, Huisman HJ, Laheij RJF, et al. (2003) Discrimination of prostate cancer from peripheral zone and central gland tissue using dynamic contrast-enhanced MR imaging. Radiology 229:248–254PubMedCrossRefGoogle Scholar
  10. 10.
    Jung JA, Coakley FV, Qayyum A, et al. (2004) Endorectal MR spectroscopic imaging of the prostate:investigation of a standardized evaluation system. Radiology 233:701–708PubMedCrossRefGoogle Scholar
  11. 11.
    Kurhanewicz J, Vigneron DB, Hricak H, et al. (1986) Three dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7 cm3) spatial resolution. Radiology 198:795–805Google Scholar
  12. 12.
    Kurhanewicz J, Vigneron DB, Males RG, et al. (2000) The prostate: MR imaging and spectroscopy: present and future. Radiol Clin North Am 38:115–138PubMedCrossRefGoogle Scholar
  13. 13.
    Qayyum A, Coakley FV, Lu Y, et al. (2004) Effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 183:1079–1083PubMedGoogle Scholar
  14. 14.
    Vilanova JC, Comet J, Capdevila A, et al. (2001) The value of endorectal MR imaging to predict positive biopsies in clinically intermediate-risk prostate cancer patients. Eur Radiol 11:229–235PubMedCrossRefGoogle Scholar
  15. 15.
    Cruz M, Tsuda K, Narumi Y, et al. (2002) Characterization of low-intensity lesions in the peripheral zone of prostate on pre-biopsy endorectal coil MR imaging. Eur Radiol 12:357–365PubMedCrossRefGoogle Scholar
  16. 16.
    Claus FG, Hricak H, Hattery RR (2004) Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. Radiographics 24:S167–S180PubMedCrossRefGoogle Scholar
  17. 17.
    Scheidler J, Hedvig Hricak H, Vigneron DB, et al. (1999) Prostate cancer: Localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 213:473–480PubMedGoogle Scholar
  18. 18.
    Kaji Y, Kurhanewicz J, Hricak H, et al. (1998) Localizing prostate cancer in the presence of post-biopsy changes on MR imaging: role of proton MR spectroscopic imaging. Radiology 206:785–790PubMedGoogle Scholar
  19. 19.
    Beyersdorff D, Taupitz M, Winkelmann B, et al. (2002) Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 224:701–706PubMedCrossRefGoogle Scholar
  20. 20.
    Perrotti M, Han KR, Epstein RE, et al. (1999) Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy: a pilot study. J Urol 162:1314–1317PubMedCrossRefGoogle Scholar
  21. 21.
    Comet-batlle J, Vilanova-Busquets JC, Saladie-Roig JM, et al. (2003) Endorectal MRI in the early diagnosis of prostate cancer. Eur Urol 44:201–208PubMedCrossRefGoogle Scholar
  22. 22.
    Vilanova JC, Comet J, Barceló AJ, et al. (2004) The value of MR spectroscopic imaging for prostate cancer detection in the peripheral and transitional zone in patients with elevated PSA and negative biopsy (abstr). Radiology (p) 233:270Google Scholar
  23. 23.
    Zakian KL, Eberhardt S, Hricak H, et al. (2003) Transition zone prostate cancer: metabolic characteristics at 1H spectroscopic imaging-initial results. Radiology 229:241–247PubMedCrossRefGoogle Scholar
  24. 24.
    Zakian KL, Sircar K, Hricak H, et al. (2005) Correlation of Proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234:804–814PubMedCrossRefGoogle Scholar
  25. 25.
    Yu KK, Scheidler J, Hricak H (1999) Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 213:481–488PubMedGoogle Scholar
  26. 26.
    Wefer AE, Hricak H, Vigneron DB, et al. (2000) Sextant location of prostate cancer : comparison od sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step-section histology. J Urol 164:400–404PubMedCrossRefGoogle Scholar
  27. 27.
    Purohit RS, Shinohara K, Meng MV, Carrol PR (2003) Imaging clinically localized prostate cancer. Urol Clin North Am 30:279–293PubMedCrossRefGoogle Scholar
  28. 28.
    Huch Boni RA, Boner JA, Debatin JF, et al. (1995) Optimization of prostate carcinoma staging:comparison of imaging and clinical methods. Clin Radiol 50:593–600PubMedCrossRefGoogle Scholar
  29. 29.
    Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, Van Lier HJ, Barentsz JO (2002) Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 12:2294–2302PubMedGoogle Scholar
  30. 30.
    Jager GJ, Ruijter ET, van de Kaa CA, et al. (1996) Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol 166:845–852PubMedGoogle Scholar
  31. 31.
    Cornoud F, Flam T, Chauveinc L, et al. (2002) Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging. Radiology 224:203–210CrossRefGoogle Scholar
  32. 32.
    Wang L, Mullerad M, Chen HN, et al. (2004) Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology 232:133–139PubMedCrossRefGoogle Scholar
  33. 33.
    Coakley FV, Kurhanewicz J, Lu Y, et al. (2002) Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 223:91–97PubMedCrossRefGoogle Scholar
  34. 34.
    Partin AW, Hanks GE, Klein EA, et al. (2002) Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology 16:1024–1038PubMedGoogle Scholar
  35. 35.
    Sella T, Schwartz LH, Swindle PW, et al. (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231:379–385PubMedCrossRefGoogle Scholar
  36. 36.
    Coakley FV, The HS, Qayyum A, et al. (2004) Endorectal and MR spectroscopic imaging of locally recurrent prostate cancer after external beam radiation theraphy: preliminary experience. Radiology 233:441–448PubMedCrossRefGoogle Scholar
  37. 37.
    Mueller-Lisse UG, Vigneron DB, Hricak H, et al. (2001) Localized prostate cancer:effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology 221:380–390PubMedCrossRefGoogle Scholar
  38. 38.
    Vilanova JC, Barceló J (2005) Pelvis masculina: Próstata y testículos. In: Martí Bonmatí L, Vilanova JC (eds). Resonancia Magnética de Cuerpo. Edikamed, Barcelona, pp 149–162Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Department of Magnetic ResonanceClínica GironaGironaSpain

Personalised recommendations